Brief: UCB Upgrades Guidance, Sees 2025 Adj. EBITDA Margin Above 31%
05/12/2025 06:05
Dec 5 (Reuters) - Ucb SA UCB.BR: UCB UPGRADES 2025 FINANCIAL GUIDANCE BASED ON STRONG PERFORMANCE BRIVIACT® IS EXPECTED TO FACE LOSS-OF-EXCLUSIVITY IN 2026 2025 REVENU EXPECTED TO EXCEED EUR 7.6 BILLION 2025 ADJUSTED EBITDA MARGIN IS ANTICIPATED TO BE HIGHER THAN 31% EXPANDING USE OF BIMZELX® IN U.S. MAY AFFECT ITS NET PRICING Source text: ID:nPLXF83D69 Further company coverage: UCB.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside